KRAS
-
ASCO Update: Daraxonrasib (RMC-6236) for KRAS mutated metastatic pancreatic cancer
John Strickler, MD; Tanios S. Bekaii-Saab, MD
-
Multidisciplinary Tumor Board: Focus on Early-Stage KRAS Mutated NSCLC
Brendon Stiles, MD; Charu Aggarwal, MD, MPH
-
NSCLC: The Evolving Landscape of KRAS G12C Therapy
Timothy F. Burns, MD, PhD; Charu Aggarwal, MD, MPH
-
Targeting KRAS G12C: Focus on Lung Cancer and GI Malignancies
Charu Aggarwal, MD, MPH; John Strickler, MD
